Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Zhang, Liang ^a   Bhasin, Manoj ^a   Schor Bardach, Rachel ^a,b   Wang, Xiaoen ^a   Collins, Michael P ^c   Panka, David ^a   Putheti, Prabhakar ^a   Signoretti, Sabina ^c,d   Alsop, David C ^a   Libermann, Towia ^a   Atkins, Michael B ^a   Mier, James W ^a   Goldberg, S Nahum ^a,b   Bhatt, Rupal S ^a,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE 4 PROTEIN; ARGINASE; ARGINASE 2; INSULIN INDUCED GENE 1; INTERSTITIAL COLLAGENASE; NEUROPILIN 2; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR 1; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PARAMETERS; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; KIDNEY CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PERFUSION; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; KIDNEY TUMOR; NUDE MOUSE; TUMOR CELL LINE;

MUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PYRIDINES;

EID: 79955705800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019144     Document Type: Article

References (34)

1. Kaelin WG Jr, (2005) The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun 338: 627-638.
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134.
3. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, et al. (2009) Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 27: 4462-4468.
4. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456.
5. Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, et al. (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179-81 86; discussion 86.
6. Rini BI, Atkins MB, (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000.
7. Janne PA, Engelman JA, Johnson BE, (2005) Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23: 3227-3234.
8. Deininger M, Buchdunger E, Druker BJ, (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105: 2640-2653.
9. Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, et al. (2009) Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology 251: 731-742.
10. Huang da W, Sherman BT, Tan Q, Kir J, Liu D, et al. (2007) DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35: W169-175.
11. Tang TC, Man S, Xu P, Francia G, Hashimoto K, et al. (2010) Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12: 928-940.
12. Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, et al. (2010) Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 9: 1525-1535.
13. Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, et al. (2010) Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 10: 2793-802.
14. Bhatt RS, Zhang L, Bullock A, Wang X, Moreno K, et al. (2010) Sphingosine-1-phosphate (S1P) as a novel target in renal cancer (RCC). In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. AACR. Abstract #LB-369/8.
15. Mizukami Y, Jo WS, Duerr EM, Gala M, Li J, et al. (2005) Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11: 992-997.
16. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, et al. (2007) Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475.
17. Casanovas O, Hicklin DJ, Bergers G, Hanahan D, (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309.
18. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, et al. (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 3: 1063-71.
19. Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, et al. (2009) Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182: 29-34.
20. Zama IN, Hutson TE, Elson P, Cleary JM, Choueiri TK, et al. (2010) Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 23: 5400-6.
21. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, et al. (2011) Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. J Clin Oncol 29-suppl 7, abstract #LBA308.
22. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
23. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.
24. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr, (1995) Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1: 822-826.
25. Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, et al. (2008) Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol 191: 133-139.
26. Jones J, Libermann TA, (2007) Genomics of renal cell cancer: the biology behind and the therapy ahead. Clin Cancer Res 13: 685s-692s.
27. Ihaka R GR, (1996) A Language for Data Analysis and Graphics. Journal of Computational and Graphical Statistics 5: 299-314.
28. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
29. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
30. Sneath PHA, Sokal RR, (1973) Numerical taxonomy; the principles and practice of numerical classification. San Francisco.
31. Liu WM, Mei R, Di X, Ryder TB, Hubbell E, et al. (2002) Analysis of high density expression microarrays with signed-rank call algorithms. Bioinformatics 18: 1593-1599.
32. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
33. Simon R, Lam A, Li MC, Ngan M, Menenzes S, et al. (2007) Analysis of Gene Expression Data Using BRB-Array Tools. Cancer Inform 3: 11-17.
34. Alsop DC, Detre JA, (1996) Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab 16: 1236-1249.